Back to top
more

Cronos Group (CRON)

(Delayed Data from NSDQ)

$2.59 USD

2.59
2,348,676

+0.09 (3.60%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $2.60 +0.01 (0.39%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cronos Group (CRON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Calliditas Therapeutics AB Sponsored ADR (CALT) Surges 16.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Calliditas Therapeutics AB Sponsored ADR (CALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Abhinab Dasgupta headshot

3 Cannabis Stocks Soaring on HHS' Recommendation to DEA

by Abhinab Dasgupta

Canopy Growth (CGC), Tilray (TLRY) and Cronos (CRON) shoot up on news that the DEA is considering recommendations for low-risk reclassification of marijuana.

Pacira (PCRX) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of -3.70% and 3.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

5 Top-Performing ETFs of Last Week

by Sanghamitra Saha

Wall Street was downbeat due to rising rate worries.

Sanghamitra Saha headshot

5 Winning Inverse/leveraged ETFs of Last Week

by Sanghamitra Saha

Wall Street was downbeat last week due to rising rate worries.

Cronos Group (CRON) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cronos (CRON) delivered earnings and revenue surprises of 25% and 13.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 4.76% and 1.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Cronos (CRON) Loses -17.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Cronos (CRON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Cronos Group (CRON) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cronos (CRON) delivered earnings and revenue surprises of -180% and 7.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Cronos Group (CRON) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Andrew Rocco headshot

Pot Stocks Get Smoked: What's Behind the Move?

by Andrew Rocco

Marijuana-related stocks reversed gains from earlier in the week as revelations emerged that a recent marijuana bill is unlikely to pass.

Cronos Group (CRON) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cronos (CRON) delivered earnings and revenue surprises of -16.67% and 10.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Lags Q3 Earnings Estimates

by Zacks Equity Research

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -9.84% and 2.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cronos Group (CRON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Markets Await July Consumer Price Index Data

by Zacks Equity Research

Markets Await July Consumer Price Index Data

Mark Vickery headshot

Summer Trading Ahead of CPI Report: Pre-Markets Flat to Down

by Mark Vickery

We see a preliminary non-farm -4.6% in Q2 Productivity, better than the -5% expected and the -7.3% from Q1, which was the worst productivity report since 1947.

Cronos Group (CRON) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cronos (CRON) delivered earnings and revenue surprises of 0% and 16.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of -37.04% and 0.06%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Ideas feature highlights: ETFMG Alternative Harvest ETF and Cronos Group

by Zacks Equity Research

ETFMG Alternative Harvest ETF and Cronos Group have been highlighted in this Investment Ideas article.

Bryan Hayes headshot

Are Marijuana Stocks A 'Buy' Amid U.S. Decriminalization Bill?

by Bryan Hayes

If signed into law, it would remove marijuana from the Controlled Substances Act (CSA).

Cronos Group (CRON) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cronos (CRON) delivered earnings and revenue surprises of 0% and 7.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

USANA Health Sciences (USNA) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

USANA Health (USNA) delivered earnings and revenue surprises of 0.88% and 0.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Chemed (CHE) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 3.75% and 0.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Has CoDiagnostics, Inc. (CODX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how CoDiagnostics, Inc. (CODX) and Cronos Group (CRON) have performed compared to their sector so far this year.